Results 11 to 20 of about 63,048 (236)
Revista Española de Quimioterapia, 2021 Ceftazidime is a 3rd generation cephalosporin active against Pseudomonas aeruginosa. Avibactam is an inhibitor of class A, C and some class D β-lactamases. The antibacterial spectrum of ceftazidime-avibactam covers 95% of P. aeruginosa isolates and >99% of enterobacteria, including strains carrying extended-spectrum β-lactamases (ESBLs).
Matesanz, Mayra, Mensa, José
openaire +2 more sources
Ceftazidime-avibactam in ceftazidime-resistant infections [PDF]
The Lancet Infectious Diseases, 2016 One of the important causes of the development of resistance to β-lactam drugs is their overuse. β-lactamase inhibitors have been combined with many β-lactam drugs to resume their efficacy since the emergence of multidrugresistant organisms. Yahuda Carmeli and colleagues recommended the combination of ceftazidimeavibactam as a potential alternative to ...
Yehuda, Carmeli +4 more
openaire +5 more sources
Microbiological assay for ceftazidime injection
, 2007 A simple, sensitive, and specific biodiffusion assay for the! antibacterial ceftazidime was developed using a strain of Staphylococcus epidermidis (ATCC 12228) as the test organism.
Salgado, Hérida Regina Nunes +1 more
core +5 more sources
Ceftazidime resistance in Pseudomonas aeruginosa is multigenic and complex.
, 2023 Pseudomonas aeruginosa causes a wide range of severe infections. Ceftazidime, a cephalosporin, is a key antibiotic for treating infections but a significant proportion of isolates are ceftazidime-resistant.
Winstanley, Craig +15 more
core +1 more source
Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections [PDF]
, 1983 Thirty-six urological patients (21 male, 15 female) aged 21 to 83 years with complicated and/or hospital-acquired urinary tract infections due to sensitive bacteria were treated with ceftazidime intravenously with a daily dose of 2 g bd over 5 to 17 days.
Kurt G. Naber +5 more
core +1 more source
Integrating CRRT as a Virtual Organ Into Physiologically Based Pharmacokinetic Modeling to Optimize Antimicrobial Dosing in Septic Patients. [PDF]
CPT Pharmacometrics Syst PharmacolDevelopment and application of PBPK modeling integrating CRRT as a virtual organ to characterize antimicrobial pharmacokinetics and optimize dosing in septic patients. ABSTRACT Continuous renal replacement therapy (CRRT) extracorporeal drug removal, sepsis‐related pathophysiological alterations, and reduced pathogen susceptibility to antimicrobials can
Xing Y +7 more
europepmc +2 more sources
Revista Española de Quimioterapia, 2022 The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa,
openaire +2 more sources
Antibiotics, 2021 The purpose of this study was to explore the value of using cefepime and ceftazidime in treating patients with COVID-19. A total of 370 (162 males) patients, with RT-PCR-confirmed cases of COVID-19, were included in the study.
Ragaey A. Eid +6 more
doaj +1 more source
Antibiotics, 2021 Altered pharmacokinetics (PK) of hydrophilic antibiotics in critically ill patients is common, with possible consequences for efficacy and resistance. We aimed to describe ceftazidime population PK in critically ill patients with a proven or suspected ...
Annabel Werumeus Buning +8 more
doaj +1 more source
Siamese crocodile plasma synergizes with ceftazidime against ceftazidime-resistant Enterobacter cloacae [PDF]
, 2018 Purpose: To evaluate whether Siamese crocodile plasma exhibits antibacterial properties and if it synergizes with ceftazidime against ceftazidime-resistant Enterobacter cloacae (CREnC).Methods: Protein fractions were from crocodile plasma and tested them
Temsiripong, Yosapong +3 more
core +1 more source